Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China’s Nanjing King-Friend Takes Control Of US Injectables Specialist Meitheal

Executive Summary

China’s Nanjing King-Friend Biochemical Pharmaceutical has taken a majority stake in US generic injectables specialist Meitheal Pharmaceuticals.

You may also be interested in...



Meitheal Introduces US Enoxaparin

Meitheal has launched enoxaparin in the US following its FDA approval towards the end of last year.

Meitheal Reveals Manufacturing Expansion Plans

Meithal Pharmaceuticals has revealed future plans to expand its manufacturing capabilities as the US FDA approved a new vial manufacturing line that will double the firm’s capacity to supply the US market.

Meitheal Gets US Enoxaparin Approval

Through its partnership with majority stakeholder Nanjing King-Friend Biochemical Pharmaceutical, Meitheal Pharmaceuticals has received FDA approval for enoxaparin, a generic rival to Lovenox.

Related Content

Topics

UsernamePublicRestriction

Register

GB140592

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel